Cantor Fitzgerald analyst Kristen Kluska reiterates Sarepta Therapeutics (NASDAQ:SRPT) with a Neutral and maintains $128 price target.
Cantor Fitzgerald Reiterates Neutral on Sarepta Therapeutics, Maintains $128 Price Target
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.